drugset
drugset / Trial / NCT03564470

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

NCT03564470 ↗

Phase 2/3 Unknown 120 enrolled Nanfang Hospital, Southern Medical University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Ph-like ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, two-arm, multi-site trial PDT-Ph-like-ALL is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor chidamide and dasatinib for adult Ph-like ALL.

Timeline

Start
2016-02-14
Primary completion
2023-08-30
Completion
2023-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 10 mg Oral
Subject dasatinib anhydrous Small molecule 100 mg Oral

Indications

B-cell acute lymphoblastic leukemia